Filed by Bowne Pure Compliance
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 11-K
ANNUAL REPORT
PURSUANT TO SECTION 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
(Mark One):
     
þ   ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2007
OR
     
o   TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number 000-28782
SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN
(Full title of the plan)
SPECTRUM PHARMACEUTICALS, INC.
157 Technology Drive
Irvine, California 92618
(Name of issuer of the securities held pursuant to the plan and the address of the issuer’s and plan’s principal executive office)
 
 

 

 

TABLE OF CONTENTS

Item 1-3.
Item 4.
SIGNATURES

Table of Contents

REQUIRED INFORMATION
Item 1-3. The Spectrum Pharmaceuticals, Inc. 401(k) Plan (the “Plan”) is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). Therefore, in lieu of the requirements of Items 1-3 of Form 11-K, attached are the financial statements of the Plan for the fiscal period ended December 31, 2007, which have been prepared in accordance with the financial reporting requirements of ERISA.
Item 4. Pursuant to Section 103(c) of ERISA, and the regulations thereunder, the Plan is not required to file audited financial statements, because the Plan has fewer than 100 participants.

 

 

Table of Contents

SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN
STATEMENT OF INCOME AND EXPENSES
Year Ending December 31, 2007
         
INCOME
        
Contribution — Company Matching (co. stock)
   $ 179,471  
Contribution — Participant 401(k)
     388,587  
Investment Earnings
     104,854  
Cash Value of Surrendered Insurance
     0  
Realized Gain From Asset Sale
     0  
Insurance Premium Refunds
     0  
Other Income — Rollovers
     22,949  
Unrealized Depreciation of Assets
     (144,545 )
 
      
 
        
Total Income
   $ 551,316  
 
      
EXPENSES
        
Life Insurance Premiums Paid
   $ 0  
Payments to Participants
     141,792  
Bank Charges
     0  
Brokerage Fees
     0  
Administration Expenses Paid By the Trust
     0  
Other Miscellaneous Expenses
        
 
      
 
        
Total Expenses
   $ 141,792  
 
      
Income Over Expenses
   $ 409,524  
Assets At The Beginning Of The Plan Year
     1,244,286  
 
      
Assets At The End Of The Plan Year
   $ 1,653,810  
 
      
PLAN ASSETS AND LIABILITIES
                 
    As of     As of  
    January 1,     December 31,  
    2007     2007  
ASSETS
                
Cash (Interest Bearing)
   $ 127,183     $ 226,798  
Contribution Receivable — (Co. Match)
     31,138       0  
Contribution Receivable — (401-K)
     13,595       0  
Government Securities
     0       0  
Mutual Funds
     787,983       1,141,842  
Corporate Stocks & Bonds — (Employer Stock)
     212,126       218,411  
Real Estate and Mortgages
     0       0  
Depreciable Buildings/Property
     0       0  
Participant Loans
     72,261       66,759  
Other Assets
     0       0  
 
            
 
                
Total Assets
   $ 1,244,286     $ 1,653,810  
 
            
 
                
LIABILITIES
                
Payables
     0       0  
Acquisition Indebtedness
     0       0  
Other Liabilities
     0       0  
 
            
 
                
Total Liabilities
   $ 0     $ 0  
 
            
 
                
NET ASSETS (Assets Less Liabilities)
   $ 1,244,286     $ 1,653,810  
 
            

 

 

Table of Contents

SIGNATURES
The Plan. Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the Plan) have duly caused this annual report to be signed by the undersigned thereunto duly authorized, in the City of Irvine, State of California, on the 30th day of June, 2008.
         
    SPECTRUM PHARMACEUTICALS, INC. 401(K) PLAN
 
        
 
  By:   Spectrum Pharmaceuticals, Inc.
 
        
 
  By:   /s/ Rajesh C. Shrotriya, M.D.
 
       
 
      Rajesh C. Shrotriya, M.D.
 
      Chairman, Chief Executive Officer and President